Gilead Sciences

2 Sets of Disasters Biotech Will Pay For in 2019
2 Sets of Disasters Biotech Will Pay For in 2019
Yahoo/Motley Fool
Gilead Sciences
Yescarta
Novartis
Kymriah
Spark Therapeutics
Luxturna
Flag link:
Lessons From The Biggest Pharma Drug Launches Of All Time
Lessons From The Biggest Pharma Drug Launches Of All Time
Forbes
drug launches
Gilead Sciences
JNJ
Pfizer
Flag link:
Gilead Taps Roche Veteran Daniel O’Day as New CEO
Gilead Taps Roche Veteran Daniel O’Day as New CEO
BioSpace
Gilead Sciences
Pharma CEOs
Roche
Daniel O'Day
Flag link:
Did Gilead Sciences Make an $11 Billion Blunder?
Did Gilead Sciences Make an $11 Billion Blunder?
Motley Fool
Gilead Sciences
Pharmasset
hepatitis C
Flag link:
CEO of Chapel Hill firm talks 2 new partnerships with big pharma
CEO of Chapel Hill firm talks 2 new partnerships with big pharma
Bizjournals
Target PharmaSolutions
Gilead Sciences
Bristol-Myers Squibb
hepatitis B
NASH
Flag link:
While we wait for NASH data, Genfit reports positive elafibranor data in PBC patients
While we wait for NASH data, Genfit reports positive elafibranor data in PBC patients
Endpoints
Genfit
NASH
Gilead Sciences
Intercept Pharma
clinical trials
elafibranor
Flag link:
What do Martin Shkreli, Gilead and Takeda have in common? They all figure prominently in the new top-20 list of the world’s most expensive drugs
What do Martin Shkreli, Gilead and Takeda have in common? They all figure prominently in the new top-20 list of the world’s most expensive drugs
Endpoints
Takeda
Gilead Sciences
Martin Shkreli
drug pricing
Flag link:
China approves Descovy, Harvoni, Hemlibra
China approves Descovy, Harvoni, Hemlibra
BioCentury
China
Harvoni
Descovy
Hemlibra
Roche
Gilead Sciences
Flag link:
Gilead can now attempt at takeover of Galapagos
Gilead can now attempt at takeover of Galapagos
GoinPharma
Gilead Sciences
Galapagos
M&A
Flag link:
Could Gilead and Galapagos' JAK inhibitor lead the class? Wall Street thinks it has a chance.
Could Gilead and Galapagos' JAK inhibitor lead the class? Wall Street thinks it has a chance.
Biopharma Dive
Gilead Sciences
Galapagos
JAK inhibitors
rheumatoid arthritis
filgotinib
Flag link:
Are Gilead or Roche Interested in Buying Tesaro? Company Rumored to be on the Market
Are Gilead or Roche Interested in Buying Tesaro? Company Rumored to be on the Market
BioSpace
Tesaro
Roche
Gilead Sciences
M&A
Flag link:
Gilead’s GS-9674 shows positive action in primary sclerosing cholangitis
Gilead’s GS-9674 shows positive action in primary sclerosing cholangitis
Pharmaceutical Business Review
Gilead Sciences
GS-9674
primary sclerosing cholangitis
clinical trials
Flag link:
NASH drugs come into focus as field awaits late-stage data
NASH drugs come into focus as field awaits late-stage data
BioSpace
NASH
Intercept Pharma
Gilead Sciences
Genfit
Allergan
Flag link:
Gilead's search for the next great liver drug won't end with its FXR agonist
Gilead's search for the next great liver drug won't end with its FXR agonist
Biopharma Dive
Gilead Sciences
liver disease
GS-9674
Flag link:
Galapagos CEO says a sale to Gilead is 50% likely
Galapagos CEO says a sale to Gilead is 50% likely
GoinPharma
Galapagos
M&A
Gilead Sciences
Flag link:
Gilead Sciences and Tango Therapeutics Form Partnership Worth Up to $1.7 Billion to Develop Next-Gen Immuno-Oncology Therapies
Gilead Sciences and Tango Therapeutics Form Partnership Worth Up to $1.7 Billion to Develop Next-Gen Immuno-Oncology Therapies
CP Wire
Gilead Sciences
Tango Therapeutics
cancer immunotherapy
Flag link:
Gilead Sciences and Tango Therapeutics Form Partnership Worth Up to $1.7 Billion to Develop Next-Gen Immuno-Oncology Therapies
Gilead Sciences
Tango Therapeutics
cancer immunotherapy
Flag link:
Where Will Gilead Sciences, Inc. Be in 5 Years?
Where Will Gilead Sciences, Inc. Be in 5 Years?
Motley Fool
Gilead Sciences
Flag link:
Gilead's HIV portfolio soars, but is it enough to combat falling HCV sales?
Gilead's HIV portfolio soars, but is it enough to combat falling HCV sales?
Fierce Pharma
Gilead Sciences
HIV
Flag link:
Up on Deck! Ten Q3 Biotech Earnings Reports to Watch Next Week
Up on Deck! Ten Q3 Biotech Earnings Reports to Watch Next Week
BioSpace
earnings
biotech
Biogen
Alexion Pharmaceuticals
Bristol-Myers Squibb
Celgene
Gilead Sciences
Merck
Biomarin
Galapagos
Seattle Genetics
Dr Reddy's
Flag link:

Pages